No one could accuse uniQure N.V. of being flash with its cash and the Netherlands-based gene therapy specialist has announced another bout of restructuring designed to help progress its promising Huntington’s disease candidate.
The company has concluded a review of its operating expenses to ensure "sufficient cash resources to achieve multiple potentially meaningful value creating milestones
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?